Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China

Toripalimab (Tuoyi™) is a selective, recombinant, humanized monoclonal antibody against programmed death protein 1 (PD-1) developed by Shanghai Junshi Bioscience Co., Ltd. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. The binding of toripalimab to PD-1 is mainly att...

Full description

Bibliographic Details
Main Authors:	Lin Zhang, Bo Hao, Zhihua Geng, Qing Geng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Immunology
Subjects:	toripalimab programmed death protein 1 programmed death ligand 1 immunotherapy tumor adverse effect
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.730666/full

Similar Items

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
by: Feng Wang, et al.
Published: (2021-09-01)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019-07-01)

Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma
by: Meiyan Zhu, et al.
Published: (2024-04-01)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
by: Lin Zhang, et al.
Published: (2020-11-01)

Current Status of PD-1/PD-L1 Anti-tumor Therapy and Exploration of the Mechanism of Immune-related Adverse Events
by: YANG Leiyi, LIN Sang, XIE Qibing, YIN Geng
Published: (2022-04-01)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
by: Young Wha Koh, et al.
Published: (2017-03-01)

Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation
by: Taisuke Kaiho, et al.
Published: (2023-11-01)

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events
by: Tongji XIE, et al.
Published: (2020-07-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

Emerging role of the immunotherapy in treatment of breast cancer
by: Nagwa Abd El-Sadek Ahmed*, et al.
Published: (2021-08-01)

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
by: Xinfang Yu, et al.
Published: (2021-11-01)

Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2
by: Kun Du, et al.
Published: (2023-10-01)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
by: Xiao‐Li Wei, et al.
Published: (2020-08-01)

Expression of PD-L1 in Urothelial Carcinoma and its Association with Clinicopathological Parameters
by: Gurupriya Anand, et al.
Published: (2022-01-01)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
by: Chao Cheng, et al.
Published: (2022-09-01)

Evaluation of 124I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice
by: Haifeng Huang, et al.
Published: (2020-07-01)

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
by: Witold Zgodzinski, et al.
Published: (2018-04-01)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018-04-01)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018-05-01)

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
by: Rachel M. Gibbons Johnson, et al.
Published: (2017-08-01)

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner
by: Christodoulos Filippis, et al.
Published: (2017-12-01)

Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
by: Yuqing Bu, et al.
Published: (2023-03-01)

The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review
by: Mutiara Indah Sari, et al.
Published: (2022-08-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)

High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition
by: Nishant Thakur, et al.
Published: (2021-03-01)

PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
by: Jong-Mu Sun
Published: (2017-03-01)

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
by: Margarita Udall, et al.
Published: (2018-02-01)

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
by: Hirokazu Taniguchi, et al.
Published: (2021-04-01)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
by: Yuedi Zhang, et al.
Published: (2022-06-01)

Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study
by: Shreya Ghosh, et al.
Published: (2023-11-01)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
by: Joon Seon Song, et al.
Published: (2019-10-01)

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01)

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
by: Ran X, et al.
Published: (2017-07-01)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
by: Luisa Chocarro de Erauso, et al.
Published: (2020-04-01)

Research progress on photodynamic therapy combined with PD-1/PD-L1 inhibitors in anti-tumor therapy
by: Yu Xin, Ye Tinglu
Published: (2023-02-01)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
by: Yiming Wang, et al.
Published: (2018-03-01)

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters
by: Anoushika Mehan, et al.
Published: (2022-03-01)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
by: Rilan Bai, et al.
Published: (2022-05-01)